Published in @TheLancet, our review on #PancreaticCancer 📎Epidemiology🌎 📎Pathogenesis🔬 📎Risk factors & surveillance🕵️ 📎Diagnostics🩺 📎Treatment💊 📎Future directions🔍 … by @ammar_asrar, @ObaAtsushi, T. Seufferlein, JW Wilmink, @BasGrootKoerkam & @MarcBesselink

Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma 🔎PUMP-2 Trial @JCO_ASCO https://t.co/EMwfTeeo8Z 👉48 pts HAIP floxuridine + CTx 👉PR: 44%; DCR: 84% 👉1-year OS: 80.0% 🧐strong signal, interesting opportunity for downstaging,

As of last Friday, I am a Professor of Surgery @karolinskainst, adjunct to my position as Senior Consultant Surgeon @KarolinskaUnsju. While this is, of course, a personal achievement, it also represents recognition of all members of the @HpbKarolinska

Endoscopic or surgical #gastroenterostomy for palliation malignant gastric outlet obstruction? 🚀Today @LancetGastroHep: #ENDURO randomised multicenter trial @DPCG_official 🇳🇱 Excellent nationwide collaboration #surgery & #gastroenterology 🙌 ⏩️ https://t.co/HbwvlCrqgR

Neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer 🔎PREOPANC-2 phs 3 @LancetOncology https://t.co/zOC84qJIBX 👉FOLFIRINOX & gemcitabine-based regimens can be used in the neoadjuvant setting

#HoraEst 🎓today @nine_degraaf @UvA_Amsterdam: “Minimally invasive versus open #pancreatic #surgery” ✅Collaboration @e_mips @DPCG_official ✅81 authors, 12 countries ✅8 chapters, incl #DIPLOMA2 trial, published in @NEJMEvidence, @LancetGastroHep, @JAMASurgery,

🆕Online today: Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable #pancreaticpancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial @BasGrootKoerkam, @MarcBesselink, Dutch Pancreatic Cancer Group https://t.co/K2NvN4mzx0

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in @TheLancetOncol Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered https://t.co/9nfnPUyhCR

See our nationwide analysis on the stages of pancreatic cancer at diagnosis: - 57.5% metastatic - 10.9% LAPC - 8.2% borderline resectable - 23.4% resectable True reference as vascular contact was analyzed for >16’000 patients, no center selection. @TFStoop @MarcBesselink

🎉 Congratulations to @Hiro_Ishida_MD on successfully completing a 2-year research fellowship @CUSurgOnc ! Your dedication and hard work are truly inspiring. @chiaro_del

Resectability stages of pancreatic cancer: nationwide reference ➡️ https://t.co/satm84ppPy This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature, whereas the rate of PRPC is

Published in @BJSurgery, unique nationwide 🇳🇱 data @DPCG_official on @NCCN resectability staging of #PancreaticCancer at diagnosis: 🧷 23% PRPC 🧷 8% BRPC 🧷 11% LAPC 🧷 58% M1 … including stratification for tumour location. 👉 https://t.co/UEYpK2O7O7

HPB Journal Highlight ⭐️Ishida et al. Global survey shows big variation in how surgeons manage neck of pancreas cancers, especially with vascular involvement. Highlights the need for future studies & clearer guidelines! 🔗 https://t.co/fBiCWPhrb2 📊🌎 #PancreaticCancer #HPBSurgery

Distribution of the NCCN stages of #PancreaticCancer ? 16,412 pts (2017-2022) 🇳🇱 👉23% primary resectable 👉 8% borderline resectable 👉 11% locally advanced 👉 58% metastatic ⏩️ https://t.co/xpiQbjn4rR

Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study ⁦@BrJCancer⁩

The adjusted version with the corrected in-text citations is available online: 👉 https://t.co/Y5WVLuye5g @TheLancet

#HoraEst @ammar_asrar 🇺🇸 #PhD ceremony @amsterdamumc @nyuniversity @Panc_pals @DPCG_official on #PancreaticCancer ⏩️Amazing work!! #Thesis https://t.co/8KjqL88Psi #PhD team: Chris Wolfgang Jine He Lois Daamen

Pancreatic cancer patients aren't all the same. 🧬 The PANAMA score identifies who really benefits from post-op chemo after FOLFIRINOX—saving some from unnecessary treatment. 🔗 https://t.co/c27d0HHIoc

Nice study. Consistent with our ⁦@SWOG⁩ 1505 Study. ⁦@BJSurgery⁩ ⁦@DavendraSohal⁩ Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma

👉

Published in #BJC, our 🌎 study with 935 localized #pancreaticancer patients after resection, comparing preoperative FFX vs GnP: 📎FFX vs. GnP not associated with OS (p=0.17) 📎Effect FFX ⬆️ if lower serum CA19.9 #tumorbiology 🚨Pragmatic RCT #chemosensitivitymarkers 🔍